<div id="readability-page-1"><p>In a report released on April 13,  from Citi maintained a Buy rating on Wuxi Biologics (Cayman), with a price target of <span id="expert-recommendation-target">HK$42.00</span>. The company’s shares closed last Wednesday at HK$35.28.</p><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul>  <p>Currently, the analyst consensus on Wuxi Biologics (Cayman) is a Strong Buy with an average price target of HK$45.96, representing a 30.28% upside. In a report released on April 7, Morgan Stanley also maintained a Buy rating on the stock with a HK$50.00 price target.</p></div>

WXXWY

02269

LABU

<p>Citi has reaffirmed its Buy rating for Wuxi Biologics (Cayman) with a price target of HK$42.00, while the stock closed at HK$35.28. The analyst consensus is a Strong Buy with an average target of HK$45.96, indicating a potential upside of 30.28%. Additionally, Morgan Stanley also maintains a Buy rating with a target of HK$50.00.</p>

Tip Ranks

WuXi Biologics

WUXI BIO

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

VanEck Biotech ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

iShares Biotechnology ETF

iShares Global Healthcare

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

VG Health

Citi Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)